# Bioactive Secondary Metabolites from an Arctic Marine-Derived Strain, Streptomyces sp. MNP-1, Using the OSMAC Strategy

## TL;DR

This study explores a marine Streptomyces strain from the Arctic that produces bioactive compounds with antimicrobial and anticancer potential.

## Contribution

The study identifies 20 bioactive compounds from a novel Arctic Streptomyces strain using the OSMAC strategy.

## Key findings

- Seven compounds showed antimicrobial activity against pathogens like S. aureus and E. coli.
- Compounds 3 and 14 exhibited moderate anticancer activity against A549, MCF-7, and HepG2 cell lines.
- The strain is a prolific source of bioactive secondary metabolites with therapeutic potential.

## Abstract

An Arctic marine-derived strain, MNP-1, was characterized by a combined methodological approach, incorporating a variety of analytical techniques including morphological features, biochemical characteristics, and 16S ribosomal RNA (rRNA) sequence analysis. The chemical investigation of Streptomyces sp. MNP-1 using the OSMAC (one strain many compounds) strategy yielded the isolation of twenty known compounds (1–20), which were unambiguously identified by various spectroscopic approaches including 1H and 13C NMR and ESI-MS (previously reported data). Bioassay results indicated that compounds 2, 3, 5, 9, 14, 15, and 20 had antimicrobial activity against human pathogenic strains including Staphylococcus aureus, Escherichia coli, and Candida albicans with MIC values ranging from 4 to 32 μg/mL, and compounds 3 and 14 exhibited moderate inhibitory activity on A549, MCF-7, and HepG2 tumor lines showing IC50 values within the range of 19.88 to 35.82 µM. These findings suggest that Streptomyces sp. MNP-1 is one of the prolific manufacturers of bioactive secondary metabolites with therapeutic potential.